Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 1 von 212

Details

Autor(en) / Beteiligte
Titel
Commercial‐scale biotherapeutics manufacturing facility for plant‐made pharmaceuticals
Ist Teil von
  • Plant biotechnology journal, 2015-10, Vol.13 (8), p.1180-1190
Ort / Verlag
England: Blackwell Pub
Erscheinungsjahr
2015
Quelle
Wiley-Blackwell Journals
Beschreibungen/Notizen
  • Rapid, large‐scale manufacture of medical countermeasures can be uniquely met by the plant‐made‐pharmaceutical platform technology. As a participant in the Defense Advanced Research Projects Agency (DARPA) Blue Angel project, the Caliber Biotherapeutics facility was designed, constructed, commissioned and released a therapeutic target (H1N1 influenza subunit vaccine) in <18 months from groundbreaking. As of 2015, this facility was one of the world's largest plant‐based manufacturing facilities, with the capacity to process over 3500 kg of plant biomass per week in an automated multilevel growing environment using proprietary LED lighting. The facility can commission additional plant grow rooms that are already built to double this capacity. In addition to the commercial‐scale manufacturing facility, a pilot production facility was designed based on the large‐scale manufacturing specifications as a way to integrate product development and technology transfer. The primary research, development and manufacturing system employs vacuum‐infiltrated Nicotiana benthamiana plants grown in a fully contained, hydroponic system for transient expression of recombinant proteins. This expression platform has been linked to a downstream process system, analytical characterization, and assessment of biological activity. This integrated approach has demonstrated rapid, high‐quality production of therapeutic monoclonal antibody targets, including a panel of rituximab biosimilar/biobetter molecules and antiviral antibodies against influenza and dengue fever.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX